公司資料
Sarepta Therapeutics 股價、新聞與催化劑
- 股票代碼:
- SRPT
- 交易所:
- NASDAQ
- 產業:
- Gene Therapy
- 所在地:
- United States
股票表現
18.18 USD (+0.44%)
收盤價
最後更新: 2026年8月17日
1.72B USD
市值
股價為何變動
As of Aug 17, 2026, SRPT closed up 0.44% at $18.18. No new same-company headline was identified in the current news window.
公司概覽
Precision Genetic Medicine
Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.
ELEVIDYS
ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.
Exon-Skipping Franchise
EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.
siRNA Platform
SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Global Commercial Partnerships
Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。